HORIZON PHARMA (HZNP) Downgraded by Zacks to NEUTRAL
Zacks Investment Research downgraded shares of HORIZON PHARMA (HZNP) from OUTPERFORM to NEUTRAL on February 05, 2014, with a target price of $10.60. Horizon Pharma, Inc. is a biopharmaceutical company that is developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases […]